

**S A V E   T H E   D A T E !**

***Come and meet BioAlliance Pharma...***



***To gain a better understanding of the company, its product portfolio and its management team, BioAlliance Pharma organizes a symposium***

***"Oncology: key issues for the future"***

**Paris (France), February 1<sup>st</sup>, 2012** – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced a half-day symposium:

***"Oncology: key issues for the future"***

**On March 20, 2012 (from 9 am to 12 midday)**

**During the morning symposium, fund managers, analysts and media representatives will be invited to listen to and discuss with international leading specialists:**

- ✓ Bertrand Vergely, *Philosopher*
- ✓ Pr. David Khayat, *Professor in Oncology, La Pitié-Salpêtrière Hospital (Paris, France)*
- ✓ Pr. Philippe Merle, *Professor in Hepatology, La Croix Rousse Hospital (Lyon, France)*
- ✓ Pr. Michael Henke, *Professor in Radiotherapy, Universitätsklinikum Freiburg (Freiburg, Germany)*

**BioAlliance Pharma will be represented by:**

- ✓ Judith Greciet, *Chief Executive Officer*
- ✓ Pierre Attali, *Chief Operating Officer, Strategy and Medical Affairs*

The event will take place at BioAlliance Pharma's head office (in Paris) on Tuesday, March 20, 2012, from 9am onwards (by invitation only). The final morning's program will be soon announced.

# S A V E T H E D A T E !

*Come and meet BioAlliance Pharma...*

## **About BioAlliance Pharma**

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

### **Specialty products**

Loramyc<sup>®</sup>/Oravig<sup>®</sup> (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir<sup>®</sup> (Acyclovir Lauriad<sup>™</sup>) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad<sup>™</sup> (chronic cancer pain): Positive preliminary Phase I results

### **Orphan Oncology products**

Livatag<sup>®</sup> (Doxorubicin Transdrug<sup>™</sup>) in primary liver cancer: Authorization for Phase III clinical trial

Clonidine Lauriad<sup>™</sup> (mucositis): Phase II on going

AMEP<sup>™</sup> (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).*

#### **BioAlliance Pharma SA**

Judith Greciet, CEO

Tel +33 1 45 58 76 00

[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71

[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

#### **ALIZE RP**

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)